Payment overview · 2025
General Payments
$783.90
44 reported records · 9 companies
Healthcare provider profile · identity verified
John D West, PA C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · PINEVILLE, WV · NPI 1295826576
Verified facts
What the public records show
CMS Open Payments records show John D West, PA C received $783.90 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $178.92 | 22.8% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $165.67 | 21.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.00 | 18.4% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $136.65 | 17.4% | 8 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $66.99 | 8.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.28 | 5.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.81 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.98 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.60 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $783.90 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $165.67 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $165.04 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $148.99 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $120.44 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.74 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $66.99 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 499 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 477 | 93 |
| Omeprazole | Omeprazole | 458 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 71 |
| Gabapentin | Gabapentin | 296 | 72 |
| Potassium Chloride | Potassium Chloride | 295 | 58 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 294 | 56 |
| Montelukast Sodium | Montelukast Sodium | 294 | 67 |
| Lisinopril | Lisinopril | 281 | 58 |
| Famotidine | Famotidine | 272 | 56 |
| Furosemide | Furosemide | 268 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 267 | 43 |
| Meloxicam | Meloxicam | 244 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 62 |
| Ibuprofen | Ibuprofen | 215 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 206 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 43 |
| Losartan Potassium | Losartan Potassium | 186 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 164 | 48 |
| Metformin Hcl | Metformin Hcl | 162 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 42 |
| Prednisone | Prednisone | 141 | 98 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 30 |
| Diazepam | Diazepam | 131 | 26 |
| Metformin Hcl Er | Metformin Hcl | 130 | 23 |
| Lorazepam | Lorazepam | 123 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 18 |
| Azithromycin | Azithromycin | 103 | 81 |
| Tramadol Hcl | Tramadol Hcl | 103 | 36 |
| Fluconazole | Fluconazole | 102 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 32 |
| Clonidine Hcl | Clonidine Hcl | 99 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 18 |
| Carvedilol | Carvedilol | 96 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 16 |
| Methylprednisolone | Methylprednisolone | 90 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 23 |
| Eliquis | Apixaban | 88 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 22 |
| Trazodone Hcl | Trazodone Hcl | 87 | 21 |
| Sertraline Hcl | Sertraline Hcl | 84 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 69 |
| Ozempic | Semaglutide | 80 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 15 |
| Januvia | Sitagliptin Phosphate | 79 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 19 |
| Baclofen | Baclofen | 78 | 19 |
| Simvastatin | Simvastatin | 77 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 12 |
| Promethazine Hcl | Promethazine Hcl | 74 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 73 | 15 |
| Alprazolam | Alprazolam | 72 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 19 |
| Amoxicillin | Amoxicillin | 70 | 56 |
| Farxiga | Dapagliflozin Propanediol | 70 | 17 |
| Bupropion Xl | Bupropion Hcl | 68 | 17 |
| Buspirone Hcl | Buspirone Hcl | 67 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 15 |
| Allopurinol | Allopurinol | 64 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 11 |
| Linzess | Linaclotide | 63 | 11 |
| Ondansetron Odt | Ondansetron | 63 | 39 |
| Clonazepam | Clonazepam | 61 | 16 |
| Cefdinir | Cefdinir | 60 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Tradjenta | Linagliptin | 58 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 15 |
| Jardiance | Empagliflozin | 57 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 39 |
| Atenolol | Atenolol | 54 | suppressed |
| Entresto | Sacubitril/Valsartan | 54 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 40 |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 49 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 13 |
| Glipizide Er | Glipizide | 47 | 14 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 25 |
| Pregabalin | Pregabalin | 46 | 14 |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 14 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | 11 |
| Levofloxacin | Levofloxacin | 37 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Dutasteride | Dutasteride | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 22 |
| Glipizide | Glipizide | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 11 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Temazepam | Temazepam | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 13 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Promethegan | Promethazine Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $783.90 · 44 records | Novo Nordisk Inc | AIRSUPRA, FARXIGA, FREESTYLE LIBRE 2, JARDIANCE, LINZESS, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, UBRELVY, VERQUVO, VOQUEZNA, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error